ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tirzepatide

Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.

Drug pageTirzepatide: every studyAll 192 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 22, 202272 company-led studies, 19 open or runningNext primary completion: Nov 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly6917 open or runningphase 4since Jun 22, 2022Apr 29, 2016Nov 2026phase 1 · NCT07299084
Florida Academic Centers Research and Educationits history only11 open or runningno phasesince Mar 1, 2024Mar 1, 2024none ahead
Hudson Biotechits history only11 open or runningphase 3since Mar 8, 2026Mar 8, 2026Feb 14, 2027phase 3 · NCT07481747
Lexaria Bioscienceits history only10 open or runningphase 1since Oct 16, 2024Oct 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 42 earlier studies, Mar 19, 2019 to Oct 4, 2023.

  1. Jun 9, 2018Named tirzepatideINNProposed as its International Nonproprietary Name in WHO's List 119
  2. May 28, 2024Phase 3 study in ObesityNCT06439277 · 300 planned · United States, Argentina, Australia and more
  3. Sep 4, 20242 phase 3 studiesNCT06588296, NCT06588283
  4. Oct 4, 2024Phase 4 study in Diabetes Mellitus, Type 2NCT06635057 · 166 enrolled · Saudi Arabia, United Arab Emirates
  5. Oct 14, 2024Phase 2 study in ObesityNCT06643728 · 252 enrolled · United States
  6. Mar 3, 20252 phase 4 studiesNCT06864026, NCT06857942
  7. Mar 24, 2025Phase 2 study in ObesityNCT06901349 · United States, Argentina, Canada and more
  8. Apr 4, 20253 phase 3 studiesNCT06914895, NCT06937099, NCT06937086
  9. May 6, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT06962280 · 465 enrolled · United States, Argentina, Brazil and more
  10. Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07165028 · 4,500 planned · United States, Argentina, Australia and more
  11. Nov 19, 2025Phase 4 study in ObesityNCT07247084 · 3,000 planned · United Kingdom
  12. Dec 10, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07299084 · 40 enrolled · Singapore
  13. Feb 23, 2026Phase 4 study in Diabetes Mellitus, Type 2NCT07438444 · 344 enrolled · India
  14. Sep 1, 2026Phase 1 study in Diabetes Mellitus, Type 1NCT07803744 · 18 planned · United States
  15. Sep 9, 2026Phase 3 study in ObesityNCT07817875 · 150 planned · United States, Belgium, Israel and more

Ahead

  1. Nov 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07299084
  2. Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06962280
  3. Nov 2026Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT06914895
  4. Dec 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 1NCT07803744

TargetBeta

GIPR →GLP1R →read by rule
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
brenipatideEli Lillyphase 319
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

The newest 60 of 69 Eli Lilly leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07817875Obesity · United States, Belgium, Israel and more3RecruitingDec 2029150
NCT07803744Diabetes Mellitus, Type 1 · United States1RecruitingDec 202618
NCT07438444Diabetes Mellitus, Type 2 · India4Active, not recruitingJul 2027344
NCT07299084Diabetes Mellitus, Type 2 · Singapore1Active, not recruitingNov 202640
NCT07247084Obesity · United Kingdom4RecruitingJul 20293,000
NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more3RecruitingAug 20304,500
NCT06962280Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3Active, not recruitingNov 2026465
NCT06937099Crohn Disease · United States, Austria, Belgium and more3RecruitingMay 2028290
NCT06937086Colitis, Ulcerative · United States, Austria, Belgium and more3RecruitingApr 2028350
NCT06914895Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more3Active, not recruitingNov 2026905
NCT06901349Obesity · United States, Argentina, Canada and more2WithdrawnJun 10, 20250
NCT06864026Arthritis, Psoriatic · United States, Puerto Rico4Active, not recruitingAug 2027200
NCT06857942Psoriasis · United States4RecruitingMay 2028200
NCT06643728Obesity · United States2CompletedJan 16, 2026252
NCT06635057Diabetes Mellitus, Type 2 · Saudi Arabia, United Arab Emirates4CompletedApr 15, 2026166
NCT06588296Arthritis, Psoriatic · United States, Puerto Rico3CompletedNov 18, 2025279
NCT06588283Psoriasis · United States, Puerto Rico3CompletedJan 8, 2026281
NCT06439277Obesity · United States, Argentina, Australia and more3RecruitingOct 2027300
NCT06075667Obesity · United States, Canada, Czechia and more3Active, not recruitingJun 2, 2026160
NCT06047548Overweight · United States3CompletedJan 20, 2026441
NCT06037252Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more2Active, not recruitingJan 8, 2026414
NCT05978713Healthy · United States1CompletedMar 12, 202411
NCT05963022Diabetes Mellitus, Type 2 · China3CompletedOct 9, 2024206
NCT05810597Healthy · United States1CompletedJul 17, 202365
NCT05706506Diabetes Mellitus, Type 2 · United States4CompletedOct 31, 2023152
NCT05696847Obesity · United States1CompletedJan 16, 202528
NCT05691712Diabetes Mellitus, Type 2 · China3CompletedJul 1, 2024257
NCT05564039Diabetes Mellitus, Type 2 · United States, Belgium, Germany and more4CompletedJul 15, 2024282
NCT05556512Obesity · United States, Argentina, Australia and more3Active, not recruitingOct 202715,374
NCT05822830Obesity · United States, Puerto Rico3CompletedNov 13, 2024751
NCT05536804Overweight · United States, Austria, Canada and more2CompletedJul 6, 2026134
NCT05433584Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more4Active, not recruitingOct 21, 2025794
NCT05412004Sleep Apnea, Obstructive · United States, Australia, Brazil and more3CompletedMar 12, 2024469
NCT05260021Diabetes Mellitus · United States, Australia, Brazil and more3CompletedJul 30, 202499
NCT05024032Obesity · China3CompletedDec 27, 2022210
NCT04844918Obesity · Japan3CompletedJun 24, 2023267
NCT04847557Obesity · United States, Argentina, Brazil and more3CompletedJul 2, 2024731
NCT04660643Obesity · United States, Argentina, Brazil and more3CompletedApr 25, 2023783
NCT04657016Obesity · United States, Argentina, Brazil and more3CompletedApr 20, 2023579
NCT04657003Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3CompletedMar 16, 2023938
NCT04537923Diabetes Mellitus, Type 2 · United States, Argentina, Belgium and more3CompletedOct 11, 20221,428
NCT04407234Overweight · United States1CompletedJan 7, 202136
NCT04311424Healthy · United Kingdom1CompletedOct 2, 20206
NCT04311411Obesity · United States1CompletedDec 16, 2022114
NCT04255433Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedJun 12, 202513,299
NCT04235959Diabetes Mellitus, Type 2 · China1CompletedAug 17, 202124
NCT04184622Overweight · United States, Argentina, Brazil and more3CompletedApr 1, 20222,539
NCT04172987Healthy · United States1CompletedFeb 9, 202140
NCT04166773Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more2CompletedDec 11, 2023190
NCT04093752Diabetes Mellitus, Type 2 · Australia, China, India and more3CompletedNov 1, 2021917
NCT04081337Obesity · United States1CompletedMay 26, 202255
NCT04050670Healthy · United States1CompletedApr 3, 202054
NCT04050553Diabetes Mellitus, Type 2 · Austria1CompletedJan 25, 202242
NCT04039503Diabetes Mellitus, Type 2 · United States, Czechia, Germany and more3CompletedDec 22, 2020475
NCT04004988Healthy · Singapore1CompletedDec 16, 201947
NCT03987919Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedJan 28, 20211,879
NCT03954834Diabetes Mellitus, Type 2 · United States, India, Japan and more3CompletedOct 5, 2020478
NCT03951753Diabetes Mellitus, Type 2 · Germany1CompletedApr 8, 2021117
NCT03940742Hepatic Insufficiency · United States1CompletedSep 22, 202032
NCT03882970Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedDec 11, 20201,444

How it is read

Names in the registry

  • “Tirzepatide”, 69 entries
  • “Arm 5- Tirzepatide”, 1 entry
  • “Tirzepatide Dose 1”, 1 entry
  • “Tirzepatide Dose 2”, 1 entry
  • “TIRZEPATIDE”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.